|Bid||0.0000 x 1300|
|Ask||2.9500 x 1000|
|Day's Range||1.7950 - 1.9000|
|52 Week Range||1.7100 - 4.2100|
|Beta (3Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A look at the shareholders of Immutep Limited (ASX:IMM) can tell us which group is most powerful. Generally speaking...
Immutep Limited's (ASX:IMM): Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. With the latest financial year loss of -AU$12.7m and a...
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick the right individual stocks, you could make moreRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on March 5) AstraZeneca plc (NYSE: AZN ) Biohaven Pharmaceutical ...
Christopher Gavigan, sitting in a crisp white shirt inside a small TechCrunchconference room, radiates energy, even in a late-day interview just hoursbefore he's scheduled
Prima Games, the company that's been creating physical video game strategy guides for the past 28 years, is shutting down according to Publisher's Lunch. Prima's publisher DK's CEO Ian Hudson sent out an internal memo saying it was an "extremely difficult decision" and one that was made due to a "significant decline" in the video game guide sector per reports by Publishers Weekly. No more guides will be coming out of Prima Games, and its doors will officially close this coming spring.
In 2014 Marc Voigt was appointed CEO of Immutep Limited (ASX:IMM). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Read More...